Nilmat (Nilotinib)

Nilotinib, the active ingredient in Nilmat, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It is indicated for the treatment of chronic myeloid leukemia in adult patients, targeting the BCR‑ABL fusion protein that drives malignant cell proliferation and is used under medical supervision throughout treatment.

GNH USA supplies Nilmat as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, ensuring quality assurance, regulatory compliance and reliable logistics for global distribution.

Nilotinib is a targeted therapy used in chronic myeloid leukemia, acting on the BCR‑ABL tyrosine kinase pathway.

- Chronic phase CML: reduces disease progression and achieves cytogenetic remission. - Accelerated phase CML: improves hematologic response and delays transformation. - Blast phase CML: provides disease control when combined with other agents.

Nilmat may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Diarrhea - Fatigue

Serious or Rare Side Effects: - QT interval prolongation - Severe pancreatitis - Hepatic failure

When prescribing Nilmat, clinicians should consider several safety measures and monitoring requirements.

- Cardiac monitoring: obtain baseline and periodic ECGs to detect QT prolongation. - Liver function: assess hepatic enzymes before initiation and regularly during therapy. - Pancreatic enzymes: monitor amylase and lipase levels for signs of pancreatitis. - Drug interactions: review concomitant QT‑prolonging agents and strong CYP3A4 inhibitors. - Store at ambient temperature: keep in original container, protect from moisture and light.

Nilmat can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase nilotinib exposure. - QT‑prolonging drugs (e.g., amiodarone): additive risk of cardiac arrhythmia.

Moderate Interactions (Monitor Closely): - Antacids or proton pump inhibitors: may reduce nilotinib absorption. - St. John’s wort (CYP3A4 inducer): may lower plasma levels. - Warfarin: may require INR monitoring and dose adjustment.